MolecuLight® improves success with
Diabetic Wounds

MolecuLight-guided curettage or biopsy sampling positively predicted bacterial presence in wounds at potentially harmful levels, entirely eliminating the risk of false negative sampling.

Wound measurement accuracy was validated at >95% using the MolecuLight i:X device,​ and fluorescence imaging before and after standard debridement revealed persistence​ of bacterial fluorescence in 100% of DFUs.

Fluorescence imaging demonstrated superior sensitivity (84%) and accuracy (63%) compared to clinical signs of biofilm (sensitivity 44% and accuracy 43%) and biofilm blotting (sensitivity 24% and accuracy 40%).

MolecuLight-targeted sampling demonstrated superior accuracy versus Levine swabbing in detecting high bacterial loads, also identifying a greater diversity of bacterial species within wounds.

This study reveals the limitations of relying on clinical signs and symptoms for detecting harmful bacteria in DFUs. The concept of “chronic inhibitory bacterial load” (CIBL) is introduced, with MolecuLight imaging vastly improving its detection for better wound care.

A “before and after” cohort study showing that fluorescence imaging reduced antibiotic and antimicrobial dressing needs and wound care costs while improving foot ulcer healing rates (39% to 48%).

RCT evidence that MolecuLight imaging dramatically improved DFU healing outcomes. Wound healing rates doubled at 12-weeks (45% vs. 22%) and the presence/absence of bacterial fluorescence reliably predicted the degree of wound closure.

RCT evidence that MolecuLight imaging dramatically improved DFU healing outcomes. Wound healing rates doubled at 12-weeks (45% vs. 22%) and the presence/absence of bacterial fluorescence reliably predicted the degree of wound closure.

A “before and after” cohort study showing that fluorescence imaging reduced antibiotic and antimicrobial dressing needs and wound care costs while improving foot ulcer healing rates (39% to 48%).

This study reveals the limitations of relying on clinical signs and symptoms for detecting harmful bacteria in DFUs. The concept of “chronic inhibitory bacterial load” (CIBL) is introduced, with MolecuLight imaging vastly improving its detection for better wound care.

The presence or absence of red or cyan on bacterial fluorescence images accurately predicted the success or failure of DFU healing after acellular matrix product placement.

MolecuLight-targeted sampling demonstrated superior accuracy versus Levine swabbing in detecting high bacterial loads, also identifying a greater diversity of bacterial species within wounds.

Fluorescence imaging demonstrated superior sensitivity (84%) and accuracy (63%) compared to clinical signs of biofilm (sensitivity 44% and accuracy 43%) and biofilm blotting (sensitivity 24% and accuracy 40%).

Wound measurement accuracy was validated at >95% using the MolecuLight i:X device, and fluorescence imaging before and after standard debridement revealed persistence of bacterial fluorescence in 100% of DFUs.

MolecuLight-guided curettage or biopsy sampling positively predicted bacterial presence in wounds at potentially harmful levels, entirely eliminating the risk of false negative sampling.